Predictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment

被引:25
作者
Pielen, Amelie [1 ,2 ]
Pantenburg, Stefanie [3 ]
Schmoor, Claudia [4 ]
Schumacher, Martin [5 ]
Feltgen, Nicolas [3 ]
Junker, Bernd [1 ,2 ]
Callizo, Josep [3 ]
机构
[1] Univ Eye Hosp, Univ Med Ctr Freiburg, Freiburg, Germany
[2] Univ Eye Hosp, Hannover Med Sch, D-30625 Hannover, Germany
[3] Univ Eye Hosp, Univ Hosp Gottingen, Gottingen, Germany
[4] Univ Med Ctr Freiburg, Clin Trials Unit, Freiburg, Germany
[5] Univ Med Ctr Freiburg, Neuroradiol, Freiburg, Germany
关键词
Central retinal artery occlusion; Recombinant tissue plasminogen activator; Local intra-arterial fibrinolysis; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; THROMBOLYSIS; MULTICENTER; THERAPY; LYSIS; TIME;
D O I
10.1007/s00234-015-1588-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The study analyses patients' risk factors to determine prognostic and predictive factors in patients with acute central retinal artery occlusion (CRAO) treated in the randomized European Assessment Group for Lysis in the Eye (EAGLE) Study with local intra-arterial fibrinolysis (LIF) or conservative standard treatment (CST). These data could improve patient selection for either method. Post hoc statistical analysis of effects of risk factors on overall best corrected visual acuity (BCVA [logarithm of the minimum angle of resolution (logMAR)]) at baseline and month 1 (prognostic effect) and on the difference between outcome of CST and LIF (predictive effect) was conducted. Seventy two of 84 EAGLE datasets were included. Prognostic effect: Patients with coronary heart disease (CHD) presented worse BCVA at baseline (0.39 logMAR, p = 0.0097). Patients with time from occlusion to treatment < 12 h showed a trend to better vision gain at month 1 (-0.23 logMAR, p = 0.086), similarly smoking (-0.24 logMAR, p = 0.077). Predictive effect: Age (< 60 years favours LIF -0.54 logMAR; > 70 years favours CST 0.28 logMAR; interaction p = 0.070) and CHD (favours CST 0.44 logMAR; interaction p = 0.073) might be predictors of therapeutic outcome. There were no strong effects in multivariate analysis. CHD, time from occlusion to treatment and smoking influence BCVA at baseline and at month 1 (prognostic effect). Patients treated within 12 h are more likely to profit from treatment. In multivariate analysis, there is no clear trend to benefit from LIF even in patients with young age, no CHD and early treatment. Based on this preliminary report on a rather small sample size, we do not recommend LIF in CRAO patients.
引用
收藏
页码:1055 / 1062
页数:8
相关论文
共 22 条
[1]   Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion - The Johns Hopkins Hospital experience [J].
Aldrich, Eric M. ;
Lee, Andrew W. ;
Chen, Celia S. ;
Gottesman, Rebecca F. ;
Bahouth, Mona N. ;
Gailloud, Phillipe ;
Murphy, Kieran ;
Wityk, Robert ;
Miller, Neil R. .
STROKE, 2008, 39 (06) :1746-1750
[2]   Remote Ischemia Influences the Responsiveness of the Retina: Observations in the Rat [J].
Brandli, Alice ;
Stone, Jonathan .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (04) :2088-2096
[3]   Cardiovascular Risk Factors in Central Retinal Artery Occlusion Results of a Prospective and Standardized Medical Examination [J].
Callizo, Josep ;
Feltgen, Nicolas ;
Pantenburg, Stefanie ;
Wolf, Armin ;
Neubauer, Aljoscha Steffen ;
Jurklies, Bernhard ;
Wachter, Rolf ;
Schmoor, Claudia ;
Schumacher, Martin ;
Junker, Bernd ;
Pielen, Amelie .
OPHTHALMOLOGY, 2015, 122 (09) :1881-1888
[4]   State-of-the-art reperfusion strategies for acute ischemic stroke [J].
Cohen, Jose E. ;
Itshayek, Eyal ;
Moskovici, Samuel ;
Gomori, John M. ;
Fraifeld, Shifra ;
Eichel, Roni ;
Leker, Ronen R. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (03) :319-323
[5]   Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator A Science Advisory From the American Heart Association/American Stroke Association [J].
del Zoppo, Gregory J. ;
Saver, Jeffrey L. ;
Jauch, Edward C. ;
Adams, Harold P., Jr. .
STROKE, 2009, 40 (08) :2945-2948
[6]   Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 [J].
Feltgen, N. ;
Neubauer, A. ;
Jurklies, B. ;
Schmoor, C. ;
Schmidt, D. ;
Wanke, J. ;
Maier-Lenz, H. ;
Schumacher, M. .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 244 (08) :950-956
[7]   Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery Occlusion [J].
Hattenrach, Lars-Olof ;
Kuhli-Hattenbeach, Claudia ;
Scharrer, Inge ;
Baatz, Holger .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 146 (05) :700-706
[8]   CENTRAL RETINAL ARTERY-OCCLUSION AND RETINAL TOLERANCE TIME [J].
HAYREH, SS ;
KOLDER, HE ;
WEINGEIST, TA .
OPHTHALMOLOGY, 1980, 87 (01) :75-78
[9]   Poststroke Outcomes Vary by Pathogenic Stroke Subtype in The Atherosclerosis Risk in Communities Study [J].
Jones, Sara B. ;
Sen, Souvik ;
Lakshminarayan, Kamakshi ;
Rosamond, Wayne D. .
STROKE, 2013, 44 (08) :2307-2310
[10]   Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial [J].
la Rosa, Felipe de los Rios ;
Khoury, Jane ;
Kissela, Brett M. ;
Flaherty, Matthew L. ;
Alwell, Kathleen ;
Moomaw, Charles J. ;
Khatri, Pooja ;
Adeoye, Opeolu ;
Woo, Daniel ;
Ferioli, Simona ;
Kleindorfer, Dawn O. .
STROKE, 2012, 43 (06) :1591-1595